Delaware
(State or other jurisdiction of incorporation or organization) |
77-0551645
(I.R.S. Employer Identification No.) |
7555 Gateway Boulevard
Newark, California 94560 (Address of Principal Executive Offices) |
94560
(Zip Code) |
Large accelerated filer
|
ý
|
|
Accelerated filer
|
¨
|
Non-accelerated filer
|
¨
|
|
Smaller reporting company
|
¨
|
|
|
|
Emerging growth company
|
¨
|
Title of Securities
to be Registered |
|
Amount to be Registered (1)
|
|
Proposed Maximum Offering Price per Share (2)
|
|
Proposed Maximum Aggregate Offering Price (2)
|
|
Amount of Registration Fee
|
|||||||
Common Stock, par value $0.001 per share
|
|
|
|
|
|
|
|
|
|||||||
– 2014 Equity Incentive Plan
|
|
2,094,989
|
|
$
|
22.43
|
|
|
$
|
46,990,603.27
|
|
|
$
|
6,099.39
|
|
|
– 2014 Employee Stock Purchase Plan
|
|
300,000
|
|
$
|
22.43
|
|
|
$
|
6,729,000.00
|
|
|
$
|
873.43
|
|
|
Total
|
|
2,394,989
|
|
|
|
|
$
|
53,719,603.27
|
|
|
$
|
6,972.82
|
|
||
|
|||||||||||||||
(1)
|
Pursuant to Rule 416 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of Registrant’s common stock that become issuable under the plans set forth herein by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant’s common stock.
|
||||||||||||||
(2)
|
Estimated in accordance with Rule 457(c) and Rule 457(h) promulgated under the Securities Act solely for the purpose of calculating the registration fee. The offering price per share and the aggregate offering price are based upon the average of the high and low prices of the Registrant’s common stock as reported on the Nasdaq Global Market on January 17, 2020, in accordance with Rule 457(c) of the Securities Act.
|
Exhibit Number
|
|
Exhibit Description
|
|
Incorporated by Reference to the Company's
|
|
Filed Herewith
|
||||||
Form
|
|
File No.
|
|
Exhibit No.
|
|
Filed On
|
||||||
4.1
|
|
|
8-K
|
|
001-36297
|
|
3.1
|
|
February 11, 2014
|
|
|
|
4.2
|
|
|
S-1
|
|
333-193154
|
|
3.4
|
|
December 31, 2013
|
|
|
|
4.3
|
|
|
S-1/A
|
|
333-193154
|
|
4.4
|
|
February 3, 2014
|
|
|
|
4.4
|
|
|
S-1/A
|
|
333-193154
|
|
10.5
|
|
January 27, 2014
|
|
|
|
4.5
|
|
|
10-K
|
|
001-36297
|
|
10.6
|
|
March 4, 2016
|
|
|
|
4.6
|
|
|
10-Q
|
|
001-36297
|
|
10.3
|
|
November 10, 2015
|
|
|
|
4.7
|
|
|
10-K
|
|
001-36297
|
|
10.8
|
|
March 4, 2016
|
|
|
|
4.8
|
|
|
S-1/A
|
|
333-193154
|
|
10.7
|
|
January 27, 2014
|
|
|
|
5.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
23.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
23.2
|
|
|
|
|
|
|
|
|
|
|
X
|
|
24.1
|
|
|
|
|
|
|
|
|
|
|
X
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REVANCE THERAPEUTICS, INC.
|
|
|
|
By:
|
/s/ Mark J. Foley
|
|
Mark J. Foley
|
|
President and Chief Executive Officer
|
Signatures
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Mark J. Foley
|
|
President, Chief Executive Officer and Director
|
|
January 21, 2020
|
Mark J. Foley
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Tobin C. Schilke
|
|
Chief Financial Officer
|
|
January 21, 2020
|
Tobin C. Schilke
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Angus C. Russell
|
|
Director, Chairman
|
|
January 21, 2020
|
Angus C. Russell
|
|
|
|
|
|
|
|
|
|
/s/ Jill Beraud
|
|
Director
|
|
January 21, 2020
|
Jill Beraud
|
|
|
|
|
|
|
|
|
|
/s/ Robert Byrnes
|
|
Director
|
|
January 21, 2020
|
Robert Byrnes
|
|
|
|
|
|
|
|
|
|
/s/ Julian S. Gangolli
|
|
Director
|
|
January 21, 2020
|
Julian S. Gangolli
|
|
|
|
|
|
|
|
|
|
/s/ Phyllis Gardner
|
|
Director
|
|
January 21, 2020
|
Phyllis Gardner, M.D.
|
|
|
|
|
|
|
|
|
|
/s/ Chris Nolet
|
|
Director
|
|
January 21, 2020
|
Chris Nolet
|
|
|
|
|
|
|
|
|
|
/s/ Philip J. Vickers
|
|
Director
|
|
January 21, 2020
|
Philip J. Vickers, Ph.D.
|
|
|
|
|
By:
|
/s/ Gordon K. Ho
|
|
Gordon K. Ho
|